A phase I/II study of CP-4055 [ELACYT; Clavis Pharma] in patients with refractory/relapsed hematologic malignancies.

Trial Profile

A phase I/II study of CP-4055 [ELACYT; Clavis Pharma] in patients with refractory/relapsed hematologic malignancies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2012

At a glance

  • Drugs Elacytarabine (Primary) ; Idarubicin
  • Indications Acute myeloid leukaemia; Haematological malignancies
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 03 Sep 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 03 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Nov 2009 Planned number of patients changed from 260 to 311 as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top